The Use of DIOVAN to Reduce Post-Cardioversion Recurrence of Atrial Fibrillation Trial (the DRAFT Trial)

NCT00343499 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

200

Enrollment

OTHER

Sponsor class

Stopped Inability to recruit

Conditions

Atrial Fibrillation

Interventions

DRUG: valsartan

Sponsor

Intermountain Health Care, Inc.

Collaborators

[object Object]